The Trump administration has withdrawn its sweeping proposal to eliminate rebates from government drug plans, a White House spokesperson confirmed to POLITICO.
“Based on careful analysis and thorough consideration, the president has decided to withdraw the rebate rule,” spokesperson Judd Deere said in a statement. “The Trump administration is encouraged by continuing bipartisan conversations about legislation to reduce outrageous drug costs imposed on the American people, and President Trump will consider using any and all tools to ensure that prescription drug costs will continue to decline.”
The proposal — a centerpiece of the Trump administration’s strategy to reduce drug prices — had split HHS and the White House. HHS Secretary Alex Azar had argued that eliminating rebates would lead to lower list prices, warning in April that any policy that fails to address rebates “will simply not get list prices down.” But the proposal had faced resistance from domestic policy chief Joe Grogan and other fiscal hawks on grounds that it was too expensive — costing the government nearly $180 billion over a decade.
Some lawmakers also worried the rule would raise seniors’ Medicare Part D premiums.
But the decision prompted dismay on Thursday from at least one Republican senator, who blasted it as a gift for the pharmacy benefit managers that had lobbied heavily against the proposed rule. The decision is “a clear victory for big health care and a loss for patients,” said Sen. Mike Braun of Indiana, who has authored legislation ending rebates in the commercial market. “I will continue to push my legislation that forces these savings to be directly passed onto consumers.”
Axios first reported that the White House was pulling the rule.
In a statement today, HHS pointed to ongoing efforts to reduce drug prices.
“Secretary Azar is fighting alongside President Trump to lower prescription drug costs and protect America’s seniors,” HHS spokesperson Caitlin Oakley said. “President Trump and Secretary Azar are taking bold action to end foreign free riding, examine how to safely import lower-cost prescription drugs, empower patients with meaningful transparency, and the list goes on.”
This information is provided by https://www.politico.com/story/2019/07/11/white-house-drug-rebate-rule-1405884